Clinical Trials | October 25, 2025
Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Expanding US operations to address the increased demand for API development and manufacturing
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
This new facility strengthens Latin America as a collaborative hub
Subscribe To Our Newsletter & Stay Updated
